ENModalis Receives Donation from Swiss Patient Organization “Emily’s Future is Now”
We have received a generous financial donation from Emily’s Future is Now, a Switzerland-based patient organization dedicated to LAMA2-related congenital muscular dystrophy (LAMA2-RD).
The donation will support the continued research and development of MDL-101, Modalis’ investigational therapy for LAMA2-RD, which leverages the company’s proprietary CRISPR-GNDM® epigenome editing platform.
Emily’s Future is Now is a Swiss non-profit organization focused on raising awareness and funding research for LAMA2-RD. Driven by patients and families, the organization supports initiatives aimed at advancing effective therapies while fostering collaboration among international patient communities, researchers and advocacy organizations.
Modalis is advancing MDL-101 using its proprietary CRISPR-GNDM® technology, which enables targeted regulation of gene expression without altering the DNA sequence. Preclinical studies of MDL-101 have demonstrated promising pharmacological activity and efficacy in animal disease models, as well as favorable safety findings and target gene LAMA1 expression in non-human primate studies. The company is currently preparing its clinical development strategy toward a planned Phase 1 /2 clinical trial.
The donated funds will help accelerate these development activities and support the advancement of MDL-101 toward the clinic.
The impact of this donation on the Company’s financial results for the current fiscal year is expected to be immaterial.
About Emily’s Future is Now
Emily’s Future is Now is a Swiss non-profit patient organization dedicated to raising awareness and supporting research for LAMA2-related muscular dystrophy (LAMA2-RD). Led by patients and families, the organization works collaboratively with researchers, institutions, and advocacy groups to help accelerate the development of potential therapies. For more information, visit Emily’s Future is Now (www.emilysfuture.ch).